Market Overview

Celldex Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Added Shares

Share:
Related CLDX
Why Cowen & Co Likes Celldex Therapeutics Following Its FDA 'Breakthrough'
Biotech Stocks Moving Higher
Celldex prices equity offering (Seeking Alpha)

Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,800,000 shares of common stock at the public offering price of $7.50 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $12.7 million, after deducting underwriting discounts and commissions. The closing of the option exercise is expected to occur on February 11, 2013, subject to customary closing conditions.

Posted-In: News Offerings

 

Related Articles (CLDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters